Urologix (Urologix) ROCE % : 0.00% (As of Mar. 2015)

View and export this data going back to 1996. Start your Free Trial

What is Urologix ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Urologix's annualized ROCE % for the quarter that ended in Mar. 2015 was 0.00%.

Urologix ROCE % Historical Data

The historical data trend for Urologix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urologix ROCE % Chart

Urologix Annual Data

Trend

Jun05

Jun06

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

ROCE %

Get a 7-Day Free Trial

-24.69

-56.40

-79.77

-59.30

-71.00

Urologix Quarterly Data
	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15
ROCE %	Get a 7-Day Free Trial															-96.98	-61.66	-80.66	-87.82	-

Urologix ROCE % Calculation

Urologix's annualized ROCE % for the fiscal year that ended in Jun. 2014 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2014 )		(A: Jun. 2013 )		(A: Jun. 2014 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2014 )		(A: Jun. 2013 )		(A: Jun. 2014 )
	=	-3.999	/	( ( (12.527 - 2.637)	+	(5.667 - 4.292) )	/ 2 )
	=	-3.999	/	( (9.89	+	1.375)	/ 2 )
	=	-3.999	/	5.6325
	=	-71.00 %

Urologix's ROCE % of for the quarter that ended in Mar. 2015 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2015 )		(Q: Dec. 2014 )		(Q: Mar. 2015 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2015 )		(Q: Dec. 2014 )		(Q: Mar. 2015 )
	=	-0.636	/	( ( (5.321 - 5.118)	+	(5.023 - 6.129) )	/ 2 )
	=	-0.636	/	( ( 0.203	+	-1.106 )	/ 2 )
	=	-0.636	/	-0.4515
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2015) EBIT data.

Urologix (OTCPK:ULGX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Urologix ROCE % Related Terms

Thank you for viewing the detailed overview of Urologix's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Urologix (Urologix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Urologix Inc (OTCPK:ULGX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447

Website

http://www.urologix.com

Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.

Executives

Emery Sidney W Jr	director	C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Patrick D Spangler	director	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Gregory Fluet	director, officer: CEO	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
William M Moore	director
Guy C Jackson	director	C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Daniel J Starks	director	ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Claude Tihon	officer: Chief Technology Officer
Bobby Ivan Griffin	director	1326 SPRING VALLEY RD GOLDEN VALLEY PA 55422
David A Montecalvo	officer: VP, Product Dev. & Operations	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Susan Bartlett Foote	director	649 SUMMIT AVENUE, ST PAUL MN 55105